<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04774042</url>
  </required_header>
  <id_info>
    <org_study_id>202006016MIPB</org_study_id>
    <nct_id>NCT04774042</nct_id>
  </id_info>
  <brief_title>Probiotic Supplementation in the Dysbiosis of Bowel Preparation</brief_title>
  <official_title>Probiotic Supplementation in the Dysbiosis of Bowel Preparation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Significant changes in gut microbiota was noted after the high-volume bowel preparation with&#xD;
      PEG before colonoscopy. The dynamic changes were found to be short-term. However, the&#xD;
      perturbation pattern of gut microbiota found after bowel preparation may link to metabolic&#xD;
      syndrome and obesity. No study had investigated the supplementation of probiotic in this&#xD;
      dynamic situation before. Here we proposed this study to fulfill the knowledge gap and also&#xD;
      inquiry on the potential therapeutic strategy.1.To test the hypothesis of probiotic&#xD;
      supplementation after bowel preparation alters the composition of gut microbiota in a&#xD;
      short-term and long-term manner.2.To test the hypothesis of GI tract associated symptoms&#xD;
      affected by probiotic supplementation after bowel preparation. 3. To test the hypothesis of&#xD;
      clinical events, especially parameters of metabolic syndrome affected by probiotic&#xD;
      supplementation after bowel preparation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives: Colonoscopy is widely used for identification and treatment of colon polyps and&#xD;
      intestinal symptoms. High-volume polyethylene glycol (PEG) bowel preparation prior to&#xD;
      colonoscopy causes significant dysbiosis of gut microbiota. Currently dysbiosis of gut&#xD;
      microbiota is associated with metabolic syndrome and obesity. However, inconclusive&#xD;
      conclusions were drawn from clinical trials studying supplementary probiotics and beneficial&#xD;
      clinical effects on metabolic parameters. However, no study has addressed the effects of&#xD;
      probiotic supplementation on the labile and dynamic intestinal environment following bowel&#xD;
      preparation. Aims: Our study aims at studying the short-term and long-term changes on gut&#xD;
      microbiota following the probiotic supplementation after bowel preparation. We also aim at&#xD;
      studying the changes in abdominal symptoms and parameters of metabolic syndrome. Methods:&#xD;
      This study is a prospective, multicentered, randomized double blind three-armed&#xD;
      placebo-controlled trial. Targeted population will be those undergoing PEG bowel preparation&#xD;
      before colonoscopy. Each individual will be randomly assigned to one of the active probiotic&#xD;
      or placebo supplementation. General health parameters and anthropometric measurements, stool,&#xD;
      serum lab data, abdominal sonography, oral carnitine/choline challenge tests will be&#xD;
      analyzed. The follow-up timepoints are pre- and post-bowel preparation, receiving&#xD;
      probiotics/placebo for 8 weeks, 3 months and 6 months thereafter.Outcome measurement: Primary&#xD;
      end point: Evaluate the chronological change of gut microbiota post-bowel preparation between&#xD;
      probiotic group and placebo group. Secondary end points:To compare incidence of GI associated&#xD;
      symptoms after taking probiotics between two groups. Also evaluate the effects of probiotic&#xD;
      supplementation on parameters of metabolic syndrome, evaluate the effects on fatty liver and&#xD;
      the interaction between SNP variation and the benefit of probiotic supplementation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2021</start_date>
  <completion_date type="Anticipated">January 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Alpha diversity</measure>
    <time_frame>32 weeks</time_frame>
    <description>Change in alpha diversity of bacterial species post-bowel preparation between probiotic group and placebo group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Beta diversity</measure>
    <time_frame>32 weeks</time_frame>
    <description>Change in beta diversity of bacterial species post-bowel preparation between probiotic group and placebo group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bacterial species abundance</measure>
    <time_frame>32 weeks</time_frame>
    <description>Change in abundance of bacterial species post-bowel preparation between probiotic group and placebo group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of functional bowel symptoms</measure>
    <time_frame>32 weeks</time_frame>
    <description>Incidence of GI associated symptoms in 8 weeks (abdominal discomfort, diarrhea, constipation, bloating) after bowel preparation between probiotic group (L) and placebo group (P).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>32 weeks</time_frame>
    <description>Change in BMI pre- and post-bowel preparation after probiotic or placebo supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>32 weeks</time_frame>
    <description>Change in HOMA-IR pre- and post-bowel preparation after probiotic or placebo supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyslipidemia</measure>
    <time_frame>32 weeks</time_frame>
    <description>Change in lipid profiles (T-CHO, LDL, HDL, TG in mg/dL) pre- and post-bowel preparation after probiotic or placebo supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total cholesterol</measure>
    <time_frame>32 weeks</time_frame>
    <description>Change in Total cholesterol (mg/dL) pre- and post-bowel preparation after probiotic or placebo supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL</measure>
    <time_frame>32 weeks</time_frame>
    <description>Change in Low density lipoprotein, LDL (mg/dL) pre- and post-bowel preparation after probiotic or placebo supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL</measure>
    <time_frame>32 weeks</time_frame>
    <description>Change in high density lipoprotein, HDL (mg/dL) pre- and post-bowel preparation after probiotic or placebo supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TG</measure>
    <time_frame>32 weeks</time_frame>
    <description>Change in triglyceride, TG (mg/dL) pre- and post-bowel preparation after probiotic or placebo supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>32 weeks</time_frame>
    <description>Change in weight (Kg) pre- and post-bowel preparation after probiotic or placebo supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist</measure>
    <time_frame>32 weeks</time_frame>
    <description>Change in Waist (cm) pre- and post-bowel preparation after probiotic or placebo supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatty liver (grade)</measure>
    <time_frame>32 weeks</time_frame>
    <description>Change in fatty liver severity (grade) pre- and post-bowel preparation after probiotic or placebo supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatty liver (CAP)</measure>
    <time_frame>32 weeks</time_frame>
    <description>Change in fatty liver severity (CAP, dB/m) pre- and post-bowel preparation after probiotic or placebo supplementation</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Microbial Colonization</condition>
  <condition>Irritable Bowel Syndrome</condition>
  <condition>Metabolic Syndrome</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo HAC two packs once daily; Placebo Infloran one pill three times per day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HAC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Probiotic HAC two packs once daily; Placebo Infloran one pill three times per day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infloran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo HAC two packs once daily; Probiotic Infloran one pill three times per day for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Infloran probiotic</intervention_name>
    <description>Infloran</description>
    <arm_group_label>Infloran</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>HAC probiotic</intervention_name>
    <description>HAc probiotic</description>
    <arm_group_label>HAC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Infloran placebo</intervention_name>
    <description>Infloran placebo</description>
    <arm_group_label>HAC</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>HAC placebo</intervention_name>
    <description>HAC placebo</description>
    <arm_group_label>Infloran</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults age &gt;20&#xD;
&#xD;
          2. Undergoing colonofibroscopy (CFS) with PEG bowel preparation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Inadequate bowel preparation&#xD;
&#xD;
          2. Subjects with active cancer or IBD (inflammatory bowel disease)&#xD;
&#xD;
          3. Subjects with history of abdominal surgery (including stomach, gallbladder, pancreas,&#xD;
             small bowel, large bowel)&#xD;
&#xD;
          4. Subjects who take medication related to gastrointestinal motility within 1 months&#xD;
&#xD;
          5. Subjects who take antibiotics or probiotics within 1 months&#xD;
&#xD;
          6. Subjects under pregnancy&#xD;
&#xD;
          7. Allergic or intolerance to the study medication&#xD;
&#xD;
          8. Refused to randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li-Chun Chang, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tzu-Chan Hong, M.D.</last_name>
    <phone>886-2-972653917</phone>
    <email>edisonhong77@gmail.com</email>
  </overall_contact>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>February 25, 2021</last_update_submitted>
  <last_update_submitted_qc>February 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Infections</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Dysbiosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

